Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8437225 | EBioMedicine | 2018 | 8 Pages |
Abstract
Oncolytic virus (OV) therapy is potentially a game-changing cancer treatment that has garnered significant interest due to its versatility and multi-modal approaches towards tumor eradication. In the field of cancer immunotherapy, the immunological phenotype of the tumor microenvironment (TME) is an important determinant of disease prognosis and therapeutic success. There is accumulating data that OVs are capable of dramatically altering the TME immune landscape, leading to improved antitumor activity alone or in combination with assorted immune modulators. Herein, we review how OVs disrupt the immunosuppressive TME and can be used strategically to create a “pro-immune” microenvironment that enables and promotes potent, long-lasting host antitumor immune responses.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carole Achard, Abera Surendran, Marie-Eve Wedge, Guy Ungerechts, John Bell, Carolina S. Ilkow,